We would love to hear your thoughts about our site and services, please take our survey here.
Shaun P. I think they are “planning for the best, preparing for the worst”.
Let’s assume they haven’t had an official offer, but a how do these terms (or this number sound) type of approach. Would they have to announce this? (Sorry, not sure on the rules on this). And if they aren’t happy (or are) with it they would just carry on regardless building the company wouldn’t they?
Just my thoughts.
Intrepid - in case you missed it.
https://mobile.twitter.com/NovacytGroup/status/1372488458195861505
Who would buy? Guessing most would suspect AZN or GSK? Admittedly AZN just sold their part of Moderna for circa $1 billion and had raised money early last year.
Then GSK are getting set up to split into two separate entities. Could one of the two be in need of a diagnostic division in their future?
Nice to muse. I’ll be sitting on my shares for the foreseeable anyway.
Gundogan! This upcoming double game week will put the cat amongst the pigeons. ;)
As you say OO will take care of itself.
Tomozulu - I’m sure we will find out in the fullness of time about why we have the extra people coming on board. One thing I’m confident of is that Bossanova doesn’t spend without good reason. He has commented on the businesses low cost base as an advantage within this area and I’m sure he doesn’t want to jeopardise that. That said he won’t want to stifle the opportunities that are presenting themselves. Hold for gold and all that...
... is coming. Expect some slippage due to LFT news over next few days. Then I expect at the end of week we shall start the accent. I think we all see news on the horizon and this company will continue to flourish even after we return to our new normal. But in the meantime we have products now embedded in the NHS and thus getting further world wide recognition. Pushing products ahead of the curve in utility. And with cash at our disposal to keep innovating ahead of the larger (by comparison - tanker-like) pharma’s, the future is truly rosy for this company. Either they will continue to build up to being a mid cap company, worth multiple billions or else be taken out for minimum of double where we are currently.
Sure there is always a downside risk as with any investment. But with how they have positioned themselves and with the foresight they have shown to date (not to mention current cash pile) I only see it going one way... DYOR
Given all the extra people coming onboard at NCYT I think the extension (and phase 2) are VERY likely. Just need to be patient.
On another note with regards to the Huffington Post article ref Avacta is it just me or is something not adding up? A few weeks back the three manufacturers of the test were Surescreen, ODX and Mologics new manufacturing arm. Now it’s Avacta? Guess time will tell... just doesn’t “smell” right.
I’m not sure why they would take an LFT if they were feeling ill. If you have symptoms you are meant to go get a PCR test. LFT’s are used is to find asymptomatic people who are spreading it without knowing... ie the people who wouldn’t have got a test otherwise. That’s their benefit. Even then they still need to get checked via PCR. LFT’s do have their uses. That might not be what people here want to hear, but such is life. That said I’m very bullish about NCYT’s future.
Wasn’t ramping. Just couldn’t buy. Got there in the end though
Still can't buy. Can sell 15000 easy enough though.
Just trying to get a grands worth and no quote available. Anyone else?
Still think this part of the November R&D RNS doesn’t get enough said about it.
“Further to the announcement of Novacyt's second contract with the UK DHSC on 29 September 2020 for the supply of q16 and q32 instruments and test kits to NHS hospitals, the clinical trial is being expanded into additional settings across the UK where the Company's NPT systems are being deployed.”
Or is it just me?
With the efficacy’s not being 100% I can’t see the benefit of a vaccine passport. Not unless you are testing as well. Even at 95% efficacy that’s 1 in 20 where vaccine has not worked. Considering how many people there are on a plane with the air been recirculated that’s not good enough.